Legend Biotech Corporation (LEGN) has priced an underwritten public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 per ADS, raising approximately $226 million in gross proceeds before underwriting discounts and expenses. Each ADS represents two ordinary shares of the company.
The underwriters have been granted a 30-day option to purchase up to an additional 1.155 million ADSs at the offering price, excluding fees and commissions. All ADSs in the offering are being sold by Legend Biotech.
The company said the offering is expected to close on June 23, 2026, subject to customary closing conditions. Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities are acting as joint book-running managers for the transaction.
Legend Biotech is conducting the offering under an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission. A final prospectus supplement will be filed and made available on the SEC's website once issued.
LEGN has traded between $16.24 and $45.30 over the past year. The stock closed Wednesday's trading at $33.52, up 0.42%. During overnight trading session, the stock is at $31.70, down 5.43%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.